{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:09:12Z","timestamp":1789834152416,"version":"4.0.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nucl. Med."],"abstract":"\n Background<\/jats:title>\n It remains unclear whether dynamic amino-acid (AA) positron-emission tomography (PET) has additional diagnostic value over static AA-PET to distinguish tumor progression (TP) from treatment-related abnormalities (TRA) in patients with post-treatment glioma.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This was a retrospective study of patients with glioma with suspected TP who underwent dynamic AA-PET imaging. The final diagnoses were based on histopathology and\/or clinical-radiological follow-up. The static PET parameters included the mean and maximum tumor-to-brain ratio (TBR\n max<\/jats:sub>\n and TBR\n mean<\/jats:sub>\n , respectively) and the dynamic PET parameters included time to peak (TTP) and area under the time activity curve (AUTAC). Diagnostic accuracy was assessed using the area under the receiver operating characteristic curve (AUROC).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In total, 33 patients with adult diffuse glioma (17 females: mean age: 55.7\u2009\u00b1\u200912.2 years) were included [13 [S-methyl-\n 11<\/jats:sup>\n C]methionine ([\n 11<\/jats:sup>\n C]MET) and 20 O-(2-[\n 18<\/jats:sup>\n F]fluoroethyl)-L-tyrosine (\n 1<\/jats:sup>\n \u2078F]FET) PET examinations]. The static parameters (TBR\n mean<\/jats:sub>\n and TBR\n max<\/jats:sub>\n ) were significantly different between the TP and TRA groups when using [\n 11<\/jats:sup>\n C]MET (\n p<\/jats:italic>\n \u2009=\u20090.019 and\n p<\/jats:italic>\n \u2009=\u20090.013, respectively), resulting in very-good-to-excellent diagnostic accuracy (AUROC values of 0.85 and 0.93, respectively). The TBR\n mean<\/jats:sub>\n values derived from [\n 18<\/jats:sup>\n F]FET PET data were not significantly different between the TP and TRA groups (\n p<\/jats:italic>\n \u2009=\u20090.066). However, the [\n 18<\/jats:sup>\n F]FET PET data-derived TBR\n max<\/jats:sub>\n values were significantly higher in the individuals with TP (\n p<\/jats:italic>\n \u2009=\u20090.005), indicating very good diagnostic accuracy (AUROC\u2009=\u20090.84). The dynamic PET parameters (time to peak and area under the time activity curve) were not significantly different between the TP and TRA groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This study suggests that dynamic and static AA-PET parameters have similar diagnostic capacities to distinguish TP from TRA. While static AA-PET parameters may suffice for clinical decision-making, this study did not formally assess the incremental value of using dynamic metrics in addition to static measures.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fnume.2026.1762984","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:55:29Z","timestamp":1771397729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Rethinking dynamics: static amino acid PET parameters vs. dynamic amino acid PET parameters for the detection of tumor progression in patients with post-treatment glioma"],"prefix":"10.3389","volume":"6","author":[{"given":"Dylan","family":"Henssen","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Leipzig","place":["Leipzig, Germany"]},{"name":"Department of Medical Imaging, Radboud University Medical Center","place":["Nijmegen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rullmann","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schildan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Striepe","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Sch\u00fcrer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Scherlach","sequence":"additional","affiliation":[{"name":"Institute for Neuroradiology, University Hospital Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"J\u00e4hne","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Stassart","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, University of Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Seidel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swen","family":"Hesse","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Leipzig","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1212\/WNL.0b013e31821d74e7","article-title":"Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma","volume":"76","author":"Young","year":"2011","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/neuonc\/now058","article-title":"Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas","volume":"18","author":"Albert","year":"2016","journal-title":"Neuro Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12040844","article-title":"The utility of conventional amino acid PET radiotracers in the evaluation of glioma recurrence also in comparison with MRI","volume":"12","author":"Santo","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41582-021-00510-y","article-title":"MRI biomarkers in neuro-oncology","volume":"17","author":"Smits","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/neuonc\/noae049","article-title":"Challenges, limitations and pitfalls of PET and advanced MRI in patients with brain tumors \u2013 a report of the PET\/RANO group","volume":"26","author":"Galldiks","year":"2024","journal-title":"Neuro Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","article-title":"Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0","volume":"46","author":"Law","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3174\/ajnr.A6358","article-title":"Response assessment in neuro-oncology criteria for gliomas: practical approach using conventional and advanced techniques","volume":"41","author":"Leao","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J Thorac Oncol"},{"key":"B12","first-page":"203","article-title":"Measures of diagnostic accuracy: basic definitions","volume":"19","author":"Simundic","year":"2009","journal-title":"EJIFCC"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-15-1334","article-title":"Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET","volume":"22","author":"Kebir","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s00330-015-3691-6","article-title":"Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas","volume":"25","author":"Lohmann","year":"2015","journal-title":"Eur Radiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00259-007-0534-y","article-title":"FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading","volume":"34","author":"Popperl","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00259-012-2109-9","article-title":"MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?","volume":"39","author":"Jansen","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/neuonc\/noq196","article-title":"Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas","volume":"13","author":"Kunz","year":"2011","journal-title":"Neuro Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/s00259-007-0557-4","article-title":"Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?","volume":"34","author":"Moulin-Roms\u00e9e","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.36255\/pet-agents-for-primary-brain-tumor-imaging","volume-title":"In PET Agents for Primary Brain Tumor Imaging","author":"van der Kolk","year":"2023"},{"key":"B20","first-page":"1936","article-title":"Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo?","volume":"34","author":"Ishiwata","year":"1993","journal-title":"J Nucl Med"},{"key":"B21","first-page":"205","article-title":"Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging","volume":"40","author":"Wester","year":"1999","journal-title":"J Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2176\/nmc.oa.2018-0287","article-title":"Usefulness of [(11)C] methionine PET in the differentiation of tumefactive multiple sclerosis from high grade astrocytoma","volume":"59","author":"Hashimoto","year":"2019","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00259-005-0047-5","article-title":"Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells","volume":"33","author":"Stober","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Nuclear Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2026.1762984\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:55:30Z","timestamp":1771397730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2026.1762984\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":23,"alternative-id":["10.3389\/fnume.2026.1762984"],"URL":"https:\/\/doi.org\/10.3389\/fnume.2026.1762984","relation":{},"ISSN":["2673-8880"],"issn-type":[{"value":"2673-8880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1762984"}}